Free Trial
NASDAQ:TIL

Instil Bio 11/13/2023 Earnings Report

Instil Bio logo
$24.21 +3.19 (+15.18%)
Closing price 04:00 PM Eastern
Extended Trading
$25.11 +0.90 (+3.71%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Instil Bio EPS Results

Actual EPS
-$10.40
Consensus EPS
-$2.80
Beat/Miss
Missed by -$7.60
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Instil Bio's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Instil Bio Earnings Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat